The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders

被引:226
作者
van der Stelt, M [1 ]
Di Marzo, V [1 ]
机构
[1] CNR, Endocannabinoid Res Grp, Ist Chim Biomol, I-80078 Pozzuoli, NA, Italy
关键词
anandamide; 2-arachidonoylglycerol; cannabinoid; dopamine; movement disorder; reward;
D O I
10.1016/j.ejphar.2003.08.101
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To date, N-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol are the best studied endocannabinoids and are thought to act as retrograde messengers in the central nervous system (CNS). By activating presynaptic cannabinoid CB1 receptors, they can reduce glutamate release in dorsal and ventral striatum (nucleus accumbens) and alter synaptic plasticity, thereby modulating neurotransmission in the basal ganglia and in the mesolimbic reward system. In this review, we will focus on the role of the endocannabinoid system within these neuronal pathways and describe its effect on dopaminergic transmission and vice versa. The endocannabinoid system is unlikely to directly affect dopamine release, but can modify dopamine transmission trough trans-synaptic mechanisms, involving gamma-aminobutyric acid (GABA)ergic and glutamatergic synapses, as well as by converging signal transduction cascades of the cannabinoid and dopamine receptors. The dopamine and endocannabinoid systems exert a mutual control on each other. Cannabinergic signalling may lead to release of dopamine, which can act via dopamine D-1-like receptors as a negative feedback mechanism to counteract the effects of activation of the cannabinoid CB1 receptor. On the other hand, dopaminergic signalling via dopamine D-2-like receptors may lead to up-regulation of cannabinergic signalling, which is likely to represent a negative feedback on dopaminergic signalling. The consequences of these interactions become evident in pathological conditions in which one of the two systems is likely to be malfunctioning. We will discuss neurological and psychiatric disorders such as Parkinson's and Huntington's disease, drug addiction and schizophrenia. Furthermore, the possible role of the endocannabinoid system in disorders not necessarily depending on the dopaminergic system, such as eating disorders and anxiety, will be described. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:133 / 150
页数:18
相关论文
共 199 条
[41]  
Di Marzo V, 2000, CURR PHARM DESIGN, V6, P1361
[42]   Mesolimbic dopaminergic decline after cannabinoid withdrawal [J].
Diana, M ;
Melis, M ;
Muntoni, AL ;
Gessa, GL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (17) :10269-10273
[43]   FORMATION AND INACTIVATION OF ENDOGENOUS CANNABINOID ANANDAMIDE IN CENTRAL NEURONS [J].
DIMARZO, V ;
FONTANA, A ;
CADAS, H ;
SCHINELLI, S ;
CIMINO, G ;
SCHWARTZ, JC ;
PIOMELLI, D .
NATURE, 1994, 372 (6507) :686-691
[44]   Brain monoglyceride lipase participating in endocannabinoid inactivation [J].
Dinh, TP ;
Carpenter, D ;
Leslie, FM ;
Freund, TF ;
Katona, I ;
Sensi, SL ;
Kathuria, S ;
Piomelli, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (16) :10819-10824
[45]   DELTA9-TETRAHYDROCANNABINOL - AVERSIVE EFFECTS IN RAT AT HIGH DOES [J].
ELSMORE, TF ;
FLETCHER, GV .
SCIENCE, 1972, 175 (4024) :911-&
[46]   Towards a cannabinoid hypothesis of schizophrenia: Cognitive impairments due to dysregulation of the endogenous cannabinoid system [J].
Emrich, HM ;
Leweke, FM ;
Schneider, U .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1997, 56 (04) :803-807
[47]   Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice [J].
Fan, F ;
Tao, Q ;
Abood, M ;
Martin, BR .
BRAIN RESEARCH, 1996, 706 (01) :13-20
[48]   Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats [J].
Fattore, L ;
Spano, MS ;
Cossu, G ;
Deiana, S ;
Fratta, W .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2003, 17 (08) :1723-1726
[49]   Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats [J].
Fattore, L ;
Cossu, G ;
Martellotta, CM ;
Fratta, W .
PSYCHOPHARMACOLOGY, 2001, 156 (04) :410-416
[50]  
FEGLEY D, 2002, 7066 SOC NEUR